Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions.

ABSTRACT: With the advent of anti-amyloid monoclonal antibody (AAMA) therapy, precision diagnosis is necessary for identifying appropriate patients with cognitive disorders due to Alzheimer's disease. Therapy with AAMAs requires that candidates be diagnosed with mild cognitive impairment or mild dementia, have elevated brain amyloid-β, have good physical, psychiatric, and medical health, and lack clinical or biomarker evidence of potentially impactful non-Alzheimer brain disorders. The first three diagnostic activities are the core of the Clinical Practice Guidelines, but the last element of the precision diagnosis requires new decision-making tools for recognizing multi-etiology cognitive impairment. Within the context of shared decision-making between clinician, patient, and family, proper diagnos

SUBMITTER: Knopman DS 

PROVIDER: S-EPMC11776388 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature